Radius's Tymlos Dawdles At CHMP, No EU Opinion Yet

Radius Health has a new CEO, but the company's path to the EU market for its novel osteoporosis therapy Tymlos looks still subject to questions at this week's meeting of the European Medicines Agency’s CHMP.

The winding road of Tianmen mountain national park, Hunan province, China
Winding Road To Approval • Source: Shutterstock

Radius Health Inc.'s osteoporosis therapy Tymlos (abaloparatide) is enjoying a free run at the US market with the recent delay to its rival Evenity (romosozumab) in the novel anabolic therapy space, but there still seem to be some blocks on its path to the EU market.

Radius highlighted a positive opinion from the European Medicines Agency’s main scientific committee, the CHMP, for abaloparatide-SC in July as...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip